Get the Stockscreener App
22.64
2.56%
0.565
After Hours:
22.64
Neurogene Inc stock is traded at $22.64, with a volume of 456.92K.
It is up +2.56% in the last 24 hours and up +47.68% over the past month.
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.
See More
Previous Close:
$22.07
Open:
$21.78
24h Volume:
456.92K
Relative Volume:
1.26
Market Cap:
$336.31M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-3.70%
1M Performance:
+47.68%
6M Performance:
-27.13%
1Y Performance:
+0.00%
1-Day Range:
$21.51
$23.89
1-Week Range:
$21.34
$25.35
52-Week Range:
$14.44
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Name
Neurogene Inc
Sector
Industry
Phone
(877) 237-5020
Address
535 W 24TH STREET, NEW YORK
Compare NGNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
22.64 | 336.31M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Mar-21-24 | Initiated | William Blair | Outperform |
| Jan-08-24 | Initiated | H.C. Wainwright | Buy |
| Jan-05-24 | Initiated | Stifel | Buy |
| Jan-04-24 | Initiated | TD Cowen | Outperform |
View All
Neurogene Inc Stock (NGNE) Latest News
BNP Paribas Financial Markets Purchases 1,429 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene's SWOT analysis: gene therapy stock shows promise amid risks By Investing.com - Investing.com South Africa
Neurogene's SWOT analysis: gene therapy stock shows promise amid risks - Investing.com
The Next Frontier in Neurological Treatment? Neurogene Inc's Bold Vision! - Jomfruland.net
Short Interest in Neurogene Inc. (NASDAQ:NGNE) Drops By 28.7% - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
COMMODORE CAPITAL LP Acquires 600,000 Shares in Neurogene Inc - GuruFocus.com
Neurogene Inc. (NASDAQ:NGNE) Shares Bought by Fmr LLC - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Shares Sold by Janus Henderson Group PLC - MarketBeat
Neurogene and Ventyx Biosciences rises after insider buying by executives - MSN
RTW Investments LP Buys 64,691 Shares of Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
Redmile Group LLC Has $40.46 Million Position in Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
Walleye Capital LLC Cuts Stock Holdings in Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc.NGNE - PR Newswire
Neurogene files to sell 4M shares of common stock for holders - TipRanks
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Shareholders to Reach Out - AccessWire
Neurogene Inc. sees significant stock purchases by Samsara BioCapital - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
Neurogene CEO Rachel McMinn acquires $968,999 in stock By Investing.com - Investing.com UK
Neurogene retains stock target, buy rating amid Rett syndrome trial data - Investing.com Canada
Insider Buying: Christine Cvijic Acquires 24,000 Shares of Neuro - GuruFocus.com
Neurogene president buys $491,400 in company stock By Investing.com - Investing.com Nigeria
Neurogene president buys $491,400 in company stock - Investing.com
Neurogene CEO Rachel McMinn acquires $968,999 in stock - Investing.com India
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Shareholders to Inquire about Securities Investigation - AccessWire
Neurogene retains stock target, buy rating amid Rett syndrome trial data By Investing.com - Investing.com South Africa
HC Wainwright Reaffirms Buy Rating for Neurogene (NASDAQ:NGNE) - MarketBeat
Patient dies in Neurogene trial - The Pharma Letter
Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Investors to Connect - AccessWire
BMO Capital Markets Has Lowered Expectations for Neurogene (NASDAQ:NGNE) Stock Price - Defense World
How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week - MSN
Jennison Associates LLC Makes New Investment in Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
Neurogene (NASDAQ:NGNE) Receives Buy Rating from HC Wainwright - Defense World
Neurogene patient dies in drug trial, stock surges after FDA says ‘use lower dose’ - Mugglehead
Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose - MedCity News
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Stockholders to Inquire about Securities Investigation - AccessWire
Patient dies in Neurogene’s Phase I/II Rett syndrome trial - Yahoo Finance
Neurogene drops high-dose arm in Rett study after death - pharmaphorum
Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial - Yahoo Finance
Neurogene reports patient death in Rett syndrome trial - Investing.com
Neurogene reports patient death in Rett syndrome trial By Investing.com - Investing.com Australia
Neurogene Adjusts Clinical Trial After Setback - TipRanks
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Investors to Learn More About the Investigation - AccessWire
Leerink Partnrs Forecasts Reduced Earnings for Neurogene - MarketBeat
FY2024 EPS Estimates for Neurogene Cut by William Blair - MarketBeat
FY2024 EPS Estimates for Neurogene Raised by HC Wainwright - MarketBeat
Stifel stays positive on Neurogene stock amid regulatory clarity on Rett trial - Investing.com
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Neurogene price target lowered to $45 from $60 at BMO Capital - TipRanks
RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More - BioSpace
Neurogene Inc Stock (NGNE) Financials Data
There is no financial data for Neurogene Inc (NGNE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Neurogene Inc Stock (NGNE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cvijic Christine Mikail | President and CFO |
Nov 22 '24 |
Buy |
20.48 |
24,000 |
491,400 |
76,844 |
| McMinn Rachel | Chief Executive Officer |
Nov 22 '24 |
Buy |
20.40 |
47,500 |
969,000 |
1,297,859 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):